Skye Bioscience, Inc.

NasdaqGM:SKYE Rapport sur les actions

Capitalisation boursière : US$168.7m

Skye Bioscience Croissance future

Future contrôle des critères 0/6

Skye Bioscience's earnings are forecast to decline at 26.8% per annum. EPS is expected to decline by 13% per annum.

Informations clés

-26.8%

Taux de croissance des bénéfices

-13.0%

Taux de croissance du BPA

Biotechs croissance des bénéfices27.1%
Taux de croissance des recettesn/a
Rendement futur des capitaux propresn/a
Couverture par les analystes

Good

Dernière mise à jour30 Sep 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11
Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:SKYE - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/2026N/A-52-46-334
12/31/2025N/A-40-25-266
12/31/2024N/A-31-27-226
6/30/2024N/A-42-20-20N/A
3/31/2024N/A-37-15-15N/A
12/31/2023N/A-38-14-14N/A
9/30/2023N/A-43-15-15N/A
6/30/2023N/A-21-13-13N/A
3/31/2023N/A-22-14-14N/A
12/31/2022N/A-19-13-13N/A
9/30/2022N/A-12-10-10N/A
6/30/2022N/A-11-9-9N/A
3/31/2022N/A-9-8-8N/A
12/31/2021N/A-9-7-6N/A
9/30/2021N/A-8-6-6N/A
6/30/2021N/A-7-7-7N/A
3/31/2021N/A-6-6-6N/A
12/31/2020N/A-7-6-6N/A
9/30/2020N/A0-6-6N/A
6/30/2020N/A-4-5-5N/A
3/31/2020N/A13-6-6N/A
12/31/2019N/A1-6-6N/A
9/30/2019N/A-10-6-6N/A
6/30/2019N/A-7-5-5N/A
3/31/2019N/A-26-4-4N/A
12/31/2018N/A-19-4-4N/A
9/30/2018N/A-14-5-5N/A
6/30/2018N/A-12-4-4N/A
3/31/2018N/A-10N/A-4N/A
12/31/2017N/A-4N/A-3N/A
9/30/2017N/A-5N/A-2N/A
6/30/2017N/A-5N/A-2N/A
3/31/2017N/A-4N/A-3N/A
12/31/2016N/A-4N/A-4N/A
9/30/2016N/A-3N/A-4N/A
6/30/2016N/A-3N/A-5N/A
3/31/2016N/A-6N/A-4N/A
12/31/2015N/A-5N/A-4N/A
9/30/2015N/A-6N/A-3N/A
6/30/2015N/A-6N/A-3N/A
3/31/2015N/A-4N/A-3N/A
12/31/2014N/A-3N/A-2N/A
9/30/2014N/A-1N/A-1N/A
6/30/2014N/A0N/A0N/A
3/31/2014N/A0N/AN/AN/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: SKYE is forecast to remain unprofitable over the next 3 years.

Bénéfices vs marché: SKYE is forecast to remain unprofitable over the next 3 years.

Croissance élevée des bénéfices: SKYE is forecast to remain unprofitable over the next 3 years.

Chiffre d'affaires vs marché: Insufficient data to determine if SKYE's revenue is forecast to grow faster than the US market.

Croissance élevée des revenus: SKYE is forecast to have no revenue next year.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if SKYE's Return on Equity is forecast to be high in 3 years time


Découvrir les entreprises en croissance